Core Viewpoint - Bridger Management has completely liquidated its position in Masimo, indicating a significant shift in investment strategy and potentially reflecting concerns about the company's recent performance and market conditions [2][9]. Company Overview - Masimo is a prominent provider of advanced noninvasive monitoring technologies and hospital automation solutions, focusing on innovation in patient care and leveraging proprietary signal extraction technologies [5]. - The company's market capitalization stands at $9.6 billion, with a revenue of $1.5 billion and a net income of -$207.7 million for the trailing twelve months (TTM) [4]. Recent Developments - Following a lackluster quarter where Masimo's shares dipped approximately 12%, the company announced an acquisition deal at $180 per share, valued at around $9.9 billion, which led to a 34% increase in stock price shortly thereafter [9]. - As of the latest data, Masimo shares were priced at $178.24, reflecting a 5% increase over the past year, compared to a 15% gain for the S&P 500 [7]. Market Position and Strategy - Masimo's diversified product portfolio includes noninvasive patient monitoring technologies such as pulse oximetry and hospital automation platforms, serving a wide range of clients including hospitals and home care providers [8]. - The company generates revenue through direct sales, distributors, and OEM partnerships, positioning itself as a key player in the medical instruments and supplies industry [5][8]. Investment Implications - The exit of Bridger Management from Masimo may highlight the importance of timing in investment decisions, especially in the context of mid-cap medtech companies facing variable hospital spending and product cycle shifts [9]. - The current portfolio of Bridger Management remains heavily weighted towards large-cap, cash-generating companies, indicating a preference for stability while also leaving less room for unique catalysts like mergers and acquisitions [10].

Core Insights - Parkman Healthcare Partners disclosed a new position in Masimo Corporation by acquiring 200,000 shares worth approximately $26.01 million at the end of the fourth quarter [1][2] Company Overview - Masimo Corporation is a leading provider of advanced noninvasive monitoring technologies and hospital automation solutions, with a market capitalization of $9.4 billion and revenue of $1.5 billion [4][6] - The company reported a net income of -$151.5 million for the trailing twelve months [4] - Masimo's stock price was $175.49 as of the last trading day [4] Business Model - Masimo generates revenue primarily through the sale of proprietary medical devices and software platforms to healthcare providers and OEM partners, serving a wide range of clients including hospitals and emergency medical services [9] Recent Developments - Shares of Masimo have surged 35% this year, largely due to the announcement of an acquisition deal valued at approximately $9.9 billion, with a cash offer of $180 per share [8] - The acquisition is expected to close in the second half of the year, highlighting the strategic value of Masimo's technology and hospital relationships [11] Investment Implications - The new stake by Parkman Healthcare Partners represents 2.48% of its $1.05 billion in reportable U.S. equity assets as of December 31, 2025, indicating a strategic focus on companies with strong intellectual property and durable demand [8][11]